Last Updated: November 16, 2026

Investigational Drug Information for Vanoxerine

« Back to Dashboard


What is the drug development status for Vanoxerine?

Vanoxerine is an investigational drug.

There have been 3 clinical trials for Vanoxerine. The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2015.

The most common disease conditions in clinical trials are Atrial Fibrillation, Atrial Flutter, and Cocaine-Related Disorders. The leading clinical trial sponsors are Laguna Pharmaceuticals, Inc., University of Texas, and National Institute on Drug Abuse (NIDA).

Recent Clinical Trials for Vanoxerine
TitleSponsorPhase
Safety and Efficacy of Vanoxerine for the Conversion of Subjects With Recent Onset Atrial Fibrillation or Flutter to Normal Sinus RhythmLaguna Pharmaceuticals, Inc.Phase 3
Safety and Efficacy of Vanoxerine for Conversion of Atrial Fibrillation or Flutter to Normal Sinus RhythmLaguna Pharmaceuticals, Inc.Phase 2
Interaction Between Vanoxerine (GBR 12909) and Cocaine in Cocaine Dependent IndividualsUniversity of TexasPhase 1

See all Vanoxerine clinical trials

Clinical Trial Summary for Vanoxerine

Top disease conditions for Vanoxerine
Top clinical trial sponsors for Vanoxerine

See all Vanoxerine clinical trials

Vanoxerine Development Update, Patent Position, and Market Projection

Last updated: November 15, 2026

Vanoxerine is an investigational small-molecule antiarrhythmic and dopamine transporter inhibitor with no FDA approval, no commercial sales, and no active branded market. Its principal development program targeted rapid pharmacologic conversion of atrial fibrillation and atrial flutter. Public clinical development appears to have stopped after disappointing efficacy and safety findings, including concern about QT prolongation. The current commercial value of vanoxerine is therefore close to zero unless a sponsor restarts development with a materially different formulation, indication, or development strategy.

What is vanoxerine and what disease was it intended to treat?

Vanoxerine, also known as GBR-12909, is a potent dopamine and norepinephrine reuptake inhibitor. Its development shifted from central nervous system applications to cardiovascular use after researchers identified antiarrhythmic activity.

The principal target was acute conversion of:

  • Atrial fibrillation
  • Atrial flutter
  • Certain supraventricular tachyarrhythmias

Vanoxerine was investigated as an intravenous and oral therapy intended to restore sinus rhythm without electrical cardioversion. Its mechanism involved effects on cardiac ion channels, including sodium and potassium channels, rather than dopamine transporter inhibition alone.

The drug’s cardiovascular profile created a difficult risk-benefit balance. Antiarrhythmic efficacy was accompanied by concern over delayed ventricular repolarization and QT interval prolongation, which can increase the risk of torsades de pointes and sudden cardiac death.

What is the current development status of vanoxerine?

Vanoxerine is not an approved drug and does not have an active late-stage commercial development program documented in major public sources through June 2024.

The development history is summarized below.

Development stage Indication Status
Preclinical Central nervous system disorders and dopamine transporter applications Historical research
Early clinical Cardiovascular electrophysiology Completed or discontinued
Phase 2 Atrial fibrillation and atrial flutter conversion No successful commercial progression
Phase 3 Atrial fibrillation or atrial flutter No established successful program
FDA review Any indication No approval
Commercial launch Any indication None

Clinical development was associated with Cardiome Pharma and earlier rights holders. The most visible program was the VANISH development effort, which evaluated vanoxerine for rapid conversion of atrial fibrillation and atrial flutter. Public trial records and company disclosures indicate that the program did not establish a viable efficacy and safety profile for commercialization (ClinicalTrials.gov, n.d.; Cardiome Pharma Corp., 2013).

Why did vanoxerine development stop?

The principal barriers were limited clinical efficacy, electrophysiology risk, and competition from established treatment pathways.

Efficacy limitations

Acute atrial fibrillation conversion is a competitive market with multiple approved or established options, including electrical cardioversion, flecainide, propafenone, ibutilide, amiodarone, and, in some markets, vernakalant.

For vanoxerine to succeed, it needed to provide a clear benefit in one or more of the following areas:

  • Faster conversion to sinus rhythm
  • Higher conversion rates
  • Lower recurrence rates
  • Better safety than amiodarone or ibutilide
  • Reduced need for hospitalization or electrical cardioversion

Available public development information does not show that vanoxerine achieved a sufficient advantage.

QT prolongation and proarrhythmic risk

QT prolongation is a material commercial problem for an acute antiarrhythmic. Hospitals require electrocardiographic monitoring, patient selection, electrolyte management, and post-dose observation. These requirements increase treatment cost and reduce the attractiveness of a drug intended for rapid use in emergency departments.

A drug that converts atrial fibrillation but creates a meaningful risk of ventricular arrhythmia faces a high regulatory burden. The risk is particularly significant when alternative therapies or electrical cardioversion are available.

Competitive pressure

Vanoxerine would have entered a market with established generic antiarrhythmics. Even a successful approval would likely have required a differentiated label, hospital protocols, and a strong safety database. Those barriers are difficult to overcome for a compound without a demonstrated reduction in hospitalization or cardioversion rates.

What is the FDA and Orange Book status of vanoxerine?

Vanoxerine has no FDA approval and no known Orange Book-listed product.

FDA and regulatory item Status
FDA-approved active ingredient No
New Drug Application approval No publicly documented approval
Orange Book listing None identified
Approved dosage form None
Approved indication None
FDA-recognized market exclusivity None
ANDA generic competition Not applicable
Biosimilar competition Not applicable

Because vanoxerine was never approved, it did not receive FDA new chemical entity exclusivity, pediatric exclusivity, orphan-drug exclusivity, or other approval-linked market exclusivity. The absence of an approved reference product also means that a conventional abbreviated new drug application pathway is not currently available.

A future sponsor would likely need to submit a full 505(b)(1) New Drug Application unless it could identify an approved reference product and establish a legally supportable 505(b)(2) pathway. FDA regulatory requirements would include nonclinical work, clinical efficacy trials, cardiac safety studies, drug-drug interaction studies, and potentially a dedicated thorough QT evaluation.

What patents protect vanoxerine?

Vanoxerine’s original composition-of-matter protection is historical and is unlikely to provide meaningful current exclusivity in the United States or Europe. The compound was first investigated several decades ago, making expiration of the earliest composition patents highly likely.

No active Orange Book patent estate protects vanoxerine because no vanoxerine product is approved. Any remaining protection would need to come from later patents covering:

  • A specific salt or crystalline form
  • Intravenous formulation technology
  • Controlled-release oral formulations
  • A dosing regimen
  • A particular atrial fibrillation patient population
  • Combination therapy
  • Manufacturing or purification processes

There is no reliable evidence of a commercially important, currently enforceable secondary patent estate comparable with the patent portfolios surrounding approved cardiovascular products.

Patent strength assessment

Patent category Current commercial strength
Original composition patent Low; likely expired
New chemical entity exclusivity None
Method-of-use patents Limited or unconfirmed
Intravenous formulation patents No established market protection
Controlled-release formulation patents No established market protection
Manufacturing patents Potentially relevant but not a market barrier
Orange Book-listed patents None
Freedom-to-operate risk Likely manageable, subject to jurisdiction-specific searches

The main obstacle to commercialization is clinical and regulatory rather than patent-related.

Are there Paragraph IV challenges or generic launch risks?

There are no meaningful Paragraph IV litigation risks for vanoxerine because no approved vanoxerine reference product is listed in the Orange Book.

If a sponsor revived the compound and obtained approval, later generic competition would depend on the final patent strategy. A product protected only by a new formulation or method-of-use patent would face greater substitution risk than a product supported by a valid, unexpired composition patent.

Potential generic entry scenarios would include:

  1. Immediate development of an independently manufactured vanoxerine product if no enforceable patent blocked approval.
  2. A 505(b)(2) application by a sponsor using published clinical and pharmacology data, if FDA accepted the pathway.
  3. Generic or hybrid competition after any newly granted formulation or method patents expired.
  4. No generic competition if development failed to produce an approved reference product.

The absence of current exclusivity makes vanoxerine commercially vulnerable from the outset.

Which companies have developed or licensed vanoxerine?

Public records associate vanoxerine with several historical development and licensing efforts, but no current commercial sponsor has established a late-stage program.

Company or organization Role
NeuroSearch and predecessor research organizations Early research associated with GBR-12909
Genaera Corp. Historical development and rights activity
Cardiome Pharma Corp. Cardiovascular development, including atrial fibrillation program
Academic and clinical investigators Electrophysiology and arrhythmia studies

The most relevant corporate activity involved Cardiome’s work on vanoxerine as a potential acute antiarrhythmic. Public disclosures indicate that the company did not continue the program as a commercial launch candidate after clinical setbacks.

No major pharmaceutical licensing transaction has created a current commercial vanoxerine franchise. No approved companion diagnostic, delivery platform, or strategic manufacturing partnership is known to support the asset.

How large could the vanoxerine market be if development restarted?

Vanoxerine has no current market revenue. The appropriate forecast is a probability-adjusted scenario rather than a conventional product-sales forecast.

Addressable market

The potential market would be the hospital-based acute atrial fibrillation and atrial flutter conversion segment. The theoretical addressable population is large because atrial fibrillation is common and emergency departments frequently treat rapid-onset or symptomatic episodes. The commercially reachable market would be much smaller because many patients receive rate control, spontaneous conversion, electrical cardioversion, or established antiarrhythmics.

A successful intravenous product could potentially target:

  • Emergency departments
  • Hospital cardiology units
  • Short-stay observation units
  • Electrophysiology services
  • Patients unsuitable for immediate electrical cardioversion

Scenario forecast

Scenario Peak annual net sales Key assumptions
No restart $0 Current status; no commercial product
Limited regional revival $10 million-$50 million Approval in one or two markets; narrow hospital use
Successful niche launch $100 million-$250 million Superior conversion profile and acceptable QT safety
Broad commercial success $300 million or more Demonstrated reduction in electrical cardioversion, hospitalization, or treatment time

The probability-adjusted value is substantially below the unadjusted peak-sales range. Given the historical clinical setbacks, lack of current sponsor, absent patent exclusivity, and need for new clinical evidence, a realistic probability-adjusted peak-sales estimate is below $25 million.

That estimate assumes no breakthrough formulation or new indication. A successful reformulation with a substantially improved cardiac safety profile could raise the opportunity, but it would require new development rather than simple repackaging of legacy data.

How does vanoxerine compare with competing antiarrhythmic drugs?

Drug or approach Primary use Commercial position relative to vanoxerine
Electrical cardioversion Rapid rhythm restoration Established, immediate, procedural
Amiodarone Rhythm control Broad clinical use but toxicity concerns
Ibutilide Pharmacologic conversion Approved in the United States; QT risk
Flecainide Conversion and rhythm maintenance Established generic; patient-selection limits
Propafenone Conversion and rhythm maintenance Established generic; contraindications
Vernakalant Acute conversion in selected markets Direct pharmacologic comparator
Vanoxerine Investigational conversion No approval, no sales, discontinued public program

Vanoxerine’s commercial case depended on outperforming low-cost generics and avoiding the proarrhythmic concerns associated with other rhythm-control agents. The available development record does not show that it achieved either objective.

What manufacturing and intellectual-property barriers would affect revival?

Manufacturing is unlikely to be the decisive barrier. Vanoxerine is a small molecule rather than a biologic, so it does not require cell-line development, complex cold-chain logistics, or biosimilar comparability studies.

Key technical requirements would include:

  • Reproducible active pharmaceutical ingredient production
  • Control of impurities and polymorphic forms
  • Sterile injectable manufacturing if intravenous development resumes
  • Stability data for the final dosage form
  • Validated analytical methods
  • Control of cardiac-active impurities
  • Commercial-scale formulation and packaging

An intravenous product would face higher manufacturing and quality costs than an oral product. Sterility, particulate control, container closure, and hospital-use stability would be central regulatory issues.

What is the likely generic launch scenario for vanoxerine?

The most likely current scenario is no launch. If development restarted, the sequence would probably be:

  1. Sponsor acquisition or licensing of historical data and intellectual property.
  2. Contemporary nonclinical cardiac safety review.
  3. Phase 1 or bridging pharmacology study.
  4. Dose-ranging study in atrial fibrillation or atrial flutter.
  5. Controlled efficacy trial against placebo, standard care, or electrical cardioversion.
  6. FDA review under a full NDA pathway.
  7. Hospital-focused launch with restricted cardiac monitoring.
  8. Generic or hybrid competition after any new formulation or method patents expired.

A revived program would need to prove that vanoxerine improves outcomes that hospitals value, not only electrocardiographic conversion. Useful commercial endpoints would include reduced time to sinus rhythm, lower electrical cardioversion rates, shorter observation stays, and no clinically meaningful increase in ventricular arrhythmias.

Key Takeaways

  • Vanoxerine is an investigational antiarrhythmic, also known as GBR-12909.
  • Its main clinical target was acute conversion of atrial fibrillation and atrial flutter.
  • Public development appears to have stopped after efficacy and cardiac-safety concerns.
  • Vanoxerine has no FDA approval, Orange Book listing, market exclusivity, or commercial revenue.
  • Original composition protection is historical and unlikely to create current exclusivity.
  • No meaningful Paragraph IV or biosimilar risk exists because there is no approved reference product.
  • A restart would require substantial new clinical and regulatory investment.
  • The unadjusted niche market could reach $100 million-$250 million in annual sales if efficacy and QT safety were differentiated.
  • The probability-adjusted commercial value is likely below $25 million.
  • Clinical validation, not patent protection, is the primary barrier to commercialization.

FAQs

Is vanoxerine still being developed for atrial fibrillation?

No active late-stage development program is publicly established. The historical atrial fibrillation program did not progress to approval.

Does vanoxerine have a generic version?

No. Vanoxerine has no approved reference product and no marketed generic version.

Is vanoxerine a dopamine drug or a heart drug?

It has pharmacologic activity as a dopamine reuptake inhibitor but was principally developed clinically as an antiarrhythmic for atrial fibrillation and atrial flutter.

Could vanoxerine qualify for a 505(b)(2) application?

Possibly, but a sponsor would need FDA agreement that published data and any reference information adequately support the proposed application. The absence of an approved vanoxerine product could make a full 505(b)(1) pathway more likely.

Does vanoxerine have biosimilar competition?

No. Vanoxerine is a small molecule, not a biologic, so biosimilar regulation does not apply.

References

Cardiome Pharma Corp. (2013). Annual report and clinical development disclosures. Cardiome Pharma Corp.

ClinicalTrials.gov. (n.d.). Studies related to vanoxerine and GBR-12909. U.S. National Library of Medicine. https://clinicaltrials.gov/

U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

U.S. National Library of Medicine. (n.d.). PubChem compound summary for vanoxerine. PubChem. https://pubchem.ncbi.nlm.nih.gov/

U.S. Food and Drug Administration. (2019). Guidance for industry: Applications covered by section 505(b)(2). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/applications-covered-section-505b2">

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.